General information
The pharmacist has dispensed Uptravi® 200, 400, 600, 800 or 1000mcg to the patient. The health insurer will not reimburse the cost of this prescription in full. The…
Reimbursement Scheme Signifor®
The health insurer does not fully reimburse Signifor® 20mg. The producer of this medicine has therefore asked TBR Nederland to reimburse the costs of the Personal…
Update TerugBetaalRegeling Veltassa®, patiromer 8.4g
From May 1, 2023, the use of Veltassa® 8.4g will be fully reimbursed by the health insurer. For this reason the Reimbursement Scheme of Veltassa®…
Update Reimbursement Scheme Jardiance®
From April 1, 2023, the use of Jardiance® (empagliflozin) in patients with chronic heart failure regardless of ejection fraction (HfrEF, HFmrEF and HFpEF) is…
Update Reimbursement Fludrace®
The existing TBR for Fludrace® 62.50 micrograms has been expanded with the strength 31.25 micrograms. Because the health insurer has not fully reimbursed this…
PATIENTS CAN ONLY CLAIM THEIR PAID CONTRIBUTION, NOT THEIR EXCESS
General information
The pharmacist has dispensed Fludrace® 31,25 and/or 62,5 microgram to the patient. The health insurer will not…
Reimbursement Scheme Acecort®
The health insurer fully reimburses Acecort® 1, 2 and 3 mg as off March 1, 2023. The reimbursement by TBR Nederland will therefore be discontinued.
Conditions
This…
Reimbursement Scheme Forxiga® (dapagliflozine) 10 mg for the treatment of HFpEF (LVEF >40%)
The health insurer does not yet fully reimburse Forxiga® (dapagliflozin) 10 mg for the treatment of HFpEF…
Check your medicine expenses
Quickly check the maximum contribution you have to pay for your medicine
Check Medicine Expenses
General information
The pharmacist has dispensed Lokelma® 5g or 10g…
Contact number for Clients
+31 (0)88 - 00 267 02
TBR Nederland is part of Phareso, PHArmaceutical REimbursement SOlutions. Phareso is an expert in offering payment solutions for the…
